Effective management (slower dose escalation, dietary modifications like eating smaller meals and avoiding greasy foods, staying upright after eating) can make the difference between success and discontinuation
The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: A systematic review
What to Expect When Switching: First 2-4 Weeks: Side effects may recur even if you tolerated the first medication well Nausea and GI symptoms are common during transition Appetite changes may feel different Weight loss may slow temporarily Weeks 4-12: Body adjusts to new medication Side effects typically improve Appetite suppression becomes consistent Weight loss resumes or accelerates (especially switching to tirzepatide) After 3 Months: Full effects of new medication apparent Can assess if switch was beneficial May adjust dose based on results and tolerance Switching Success Rates: Most patients successfully transition between medications
In the Phase 2 retatrutide trial ( Jastreboff et al., NEJM 2023 ), body-composition imaging showed fat mass falling substantially more than lean mass, meaning the majority of the weight lost was fat
GLP-1R, GIPR, and GCGR are crucial drug targets for managing diabetes and obesity
Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index 27 kg/m 2: surmount-1 ambulatory blood pressure monitoring substudy
